<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270591</url>
  </required_header>
  <id_info>
    <org_study_id>SCC244-108</org_study_id>
    <nct_id>NCT04270591</nct_id>
  </id_info>
  <brief_title>Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haihe Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haihe Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer&#xD;
&#xD;
      Phase Ib (China only):&#xD;
&#xD;
      Approximately 15 patients&#xD;
&#xD;
      Phase Ⅱ (globally):&#xD;
&#xD;
      Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US&#xD;
      only)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase Ib study population&#xD;
&#xD;
      Approximately 90 patients with locally advanced or metastatic NSCLC (Stage IIIb, IIIc or IV)&#xD;
      including pulmonary sarcomatoid carcinoma (PSC). All patients should carry at least one of&#xD;
      the following MET alterations (confirmed by local or central laboratory):&#xD;
&#xD;
        -  Patients with METex14 skipping mutation who had previously treated by other MET&#xD;
           inhibitor(s)&#xD;
&#xD;
        -  Patients with METex14 skipping mutation who had received 3 or more lines prior systemic&#xD;
           therapies without MET inhibitor for the advanced NSCLC&#xD;
&#xD;
        -  Patients with MET amplification (GCN ≥ 4 or MET/CEP7 ratio ≥ 2)&#xD;
&#xD;
        -  Patients with MET over-expression (IHC2+) Phase II - Safety Run-in Population (US only)&#xD;
           A minimum of 6 patients who meeting the eligibility for either Phase Ib or Phase II.&#xD;
&#xD;
      Phase II study population (globally) Approximately 78 evaluable patients with locally&#xD;
      advanced or metastatic NSCLC (Stage IIIb, IIIc or IV, including PSC) harboring METex14&#xD;
      skipping mutation that have been pre-screened by local or Sponsor-designated central&#xD;
      laboratory, who are not eligible for chemotherapy or refuse of chemotherapy after&#xD;
      well-informed or have failed one or two prior lines of systemic therapies and have not had&#xD;
      prior MET inhibitor for the advanced NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase Ib：300 mg QD Glumetinib Phase II：300 mg QD Glumetinib</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ORR as determined by an Independent Radiology Review Committee (IRRC) according to RECIST Version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR(assessed as per investigators)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ORR (assessed as per investigators)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>The time from the date of first documented partial response or complete response to progressive disease or death, an average of 6 months</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of glumetinib</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>C-Met Exon 14 Mutation</condition>
  <arm_group>
    <arm_group_label>SCC244 300mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase Ib: SCC244 300mg, QD Phase II: SCC244 300mg, QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glumetinib</intervention_name>
    <description>The investigational product will be orally administrated when fasting at dose level of 300mg QD</description>
    <arm_group_label>SCC244 300mg</arm_group_label>
    <other_name>SCC244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Provide informed consent voluntarily.&#xD;
&#xD;
          2. Male and female patients ≥ 18 years of age (or having reached the age of majority&#xD;
             according to local laws and regulations, if the age is &gt; 18 years).&#xD;
&#xD;
          3. Histologically or cytologically confirmed diagnosis of NSCLC including PSC.&#xD;
&#xD;
          4. Patients with stage IIIb or IIIc NSCLC who are not candidates for definitive surgical&#xD;
             resection or concurrent chemoradiation or patients with stage IV NSCLC (AJCC version&#xD;
             8).&#xD;
&#xD;
          5. For Phase Ib study, patients should carry at least one of the following MET&#xD;
             alterations (by local or Sponsor-designated central laboratory screening):&#xD;
&#xD;
               -  METex14 skipping mutation who had previously treated by other MET inhibitor(s) or&#xD;
&#xD;
               -  METex14 skipping mutation who had received 3 or more lines prior systemic&#xD;
                  therapies without MET inhibitor for the advanced NSCLC or&#xD;
&#xD;
               -  MET amplification GCN ≥ 4 or MET/CEP7 ratio ≥ 2) or&#xD;
&#xD;
               -  MET over-expression (IHC2+).&#xD;
&#xD;
          6. For Phase II study, patients with METex14 skipping mutation in tumor or ctDNA samples&#xD;
             (local testing is acceptable for eligibility, however if the results of the central&#xD;
             laboratory is available, the report of the central laboratory shall prevail); all&#xD;
             patients in Phase II study will have confirmation of METex14 skipping mutation by&#xD;
             Sponsor-designated central laboratory but this result is not necessary for&#xD;
             eligibility.&#xD;
&#xD;
          7. Availability of tumor tissue sample (either fresh tumor biopsy or archival tumor&#xD;
             tissue sample); for patients of phase II study (not mandatory for safety run-in), if&#xD;
             screened and enrolled based on local test results of METex14 skipping, the tumor&#xD;
             tissue sample must be available for central laboratory testing before C2D1; if local&#xD;
             testing results meet the requirements, patients of phase Ib are exempt from the&#xD;
             central laboratory confirm.&#xD;
&#xD;
          8. For Phase II study, patients are not eligible for chemotherapy or refuse chemotherapy&#xD;
             after well-informed or have failed one or two prior lines of systemic therapies for&#xD;
             the advanced NSCLC.&#xD;
&#xD;
               -  Treatment failure is defined as documented disease progression or intolerance to&#xD;
                  treatment.&#xD;
&#xD;
               -  Maintenance therapy given after first line chemotherapy will be considered as&#xD;
                  part of the first line if given to patients with documented response or stable&#xD;
                  disease before starting the maintenance therapy.&#xD;
&#xD;
               -  Prior neoadjuvant/adjuvant systematic therapies will count as one prior line of&#xD;
                  treatment, provided that disease recurred within 12 months of completion of&#xD;
                  neoadjuvant/adjuvant therapy.&#xD;
&#xD;
          9. For Phase II study, at least one measurable lesion as per RECIST 1.1. (A previously&#xD;
             irradiated site lesion may only be counted as a target lesion if there is clear sign&#xD;
             of progression since the irradiation.)&#xD;
&#xD;
         10. ECOG Performance Status (PS): 0-1.&#xD;
&#xD;
         11. Adequate bone marrow reserve, renal and liver function:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 × 109/L;&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL;&#xD;
&#xD;
               -  Platelet count ≥ 75 × 109/L;&#xD;
&#xD;
               -  Serum total bilirubin ≤ ULN (≤ 3 × ULN for patients with Gilbert's syndrome);&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN&#xD;
                  (≤ 5.0 × ULN for patients with hepatic metastasis);&#xD;
&#xD;
               -  Creatinine clearance (calculated* or measured value**) ≥ 50 mL/min&#xD;
&#xD;
                    -  For calculated creatinine clearance (Ccr) value, the eligibility should be&#xD;
                       determined using the Cockcroft-Gault formula:&#xD;
&#xD;
                         -  Male Ccr (mL/mim) = body weight (kg) x (140-age)/[72 x creatinine&#xD;
                            (mg/dL)]&#xD;
&#xD;
                         -  Female Ccr (mL/min) = male Ccr x 0.85 ** A measured value&#xD;
&#xD;
               -  International normalized ratio (INR) &lt; 1.3 (or &lt; 3.0 if on anticoagulation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria shall be excluded from the study:&#xD;
&#xD;
          1. Patients with targetable activating EGFR mutation, ALK rearrangement, ROS1&#xD;
             rearrangement, BRAF mutation or NTRK fusion that have available standard of care&#xD;
             therapies.&#xD;
&#xD;
          2. Patients who have symptomatic CNS metastasis which is neurologically unstable or those&#xD;
             who have CNS disease requiring increase in the dose of steroid. (Note: Patients with&#xD;
             controlled CNS metastasis can participate in the trial. Before entering the study,&#xD;
             patients should have finished radiotherapy, or have received operation for CNS tumor&#xD;
             metastasis at least two weeks before. Patients' neurological function must be in a&#xD;
             stable state; no new neurological deficit is found during clinical examination and no&#xD;
             new problem is found during CNS imaging examinations. If patients need to use steroids&#xD;
             to treat CNS metastasis, the therapeutic dose of steroid should be stable for ≥ 3&#xD;
             months at least two weeks prior to entering the study with treatment dose no more than&#xD;
             dexamethasone 4 mg daily or an equivalent dose of steroids.)&#xD;
&#xD;
          3. Prior exposure to MET-directed therapy (except patients harboring METex14 skipping in&#xD;
             Phase Ib study).&#xD;
&#xD;
          4. Evidence of past or current primary malignancies other than NSCLC (except for&#xD;
             non-melanoma skin cancer, in situ breast cancer or in situ cervical carcinoma and&#xD;
             superficial bladder cancer, or other cancer curatively treated and with no evidence of&#xD;
             disease for at least 5 years).&#xD;
&#xD;
          5. Subjects with clinically significant cardiovascular disease, including:&#xD;
&#xD;
               -  NYHA Class III or higher congestive heart failure;&#xD;
&#xD;
               -  History or current evidence of serious uncontrolled ventricular arrhythmias&#xD;
                  requiring drug therapy;&#xD;
&#xD;
               -  Acute myocardial infarction, severe or unstable angina pectoris, coronary artery&#xD;
                  or peripheral artery bypass graft received within 6 months prior to the first&#xD;
                  dose;&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; 50%;&#xD;
&#xD;
               -  Fridericia's corrected QT interval (QTcF) &gt; 460 ms on ECG conducted during&#xD;
                  screening;&#xD;
&#xD;
               -  Congenital long QT syndrome, or any known history of torsade de pointes (TdP), or&#xD;
                  family history of unexplained sudden death;&#xD;
&#xD;
               -  Clinically uncontrolled hypertension (after standard antihypertensive treatment,&#xD;
                  systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg);&#xD;
&#xD;
          6. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of&#xD;
             starting study treatment with the exception of alopecia and grade 2 prior neuropathy.&#xD;
&#xD;
          7. Known HIV infection with a history of acquired immunodeficiency syndrome&#xD;
             (AIDS)-defining opportunity infection within the past 12 months; active hepatitis B&#xD;
             and hepatitis C. Patients whose test results meet one of the following will not be&#xD;
             enrolled:&#xD;
&#xD;
               -  for patients in China and Japan, confirmed HIV antibody positive. For patients in&#xD;
                  the US, patients with a history of HIV but no history of AIDS or an AIDS-defining&#xD;
                  opportunistic infection are allowed to be enrolled;&#xD;
&#xD;
               -  serum HBsAg positive and HBV DNA&gt;200 IU/ml or 1000 copies/mL;&#xD;
&#xD;
                  - For patients in Japan, whose results are HBsAg antigen negative; however, when&#xD;
                  HBsAb or HBcAb positive, the patients whose HBV DNA &lt; 200 IU/ml or 1000 copies/mL&#xD;
                  could be enrolled.&#xD;
&#xD;
               -  serum HCV antibody and HCV RNA positive.&#xD;
&#xD;
          8. Anticancer therapy (including chemotherapy, targeted therapy, biotherapy, hormone&#xD;
             therapy or other investigational agents) within 4 weeks or 5 times of half-lives&#xD;
             (whichever is shorter) prior to the first dose of the study drug or who have not&#xD;
             recovered from the side effect of such therapy.&#xD;
&#xD;
          9. Radical radiation therapy (including radiation therapy for over 25% bone marrow)&#xD;
             within 4 weeks prior to the first dose of the investigational product or received&#xD;
             local palliative radiation therapy for bone metastases within 2 weeks.&#xD;
&#xD;
         10. Major surgery or had significant traumatic injury within 28 days prior to the first&#xD;
             dose of the investigational product.&#xD;
&#xD;
         11. Patients who have to receive treatment (definite strong CYP3A4 inhibitor or inducer&#xD;
             [appendix 6]; in addition, herbals/supplements containing St. John's wart [Hypericum&#xD;
             perforatum L.] and Sevillia orange etc. should also be avoided.) that is prohibited&#xD;
             during the study and those who cannot discontinue drugs (e.g. antiarrhythmic agent)&#xD;
             that may lead to QTc interval prolongation or torsade de pointes. Additionally,&#xD;
             patients who have to receive treatment of strong inhibitor for CYP2C8 and/or CYP2C9&#xD;
             [appendix 6] and substrates or inhibitor for transporter [appendix 7] will be excluded&#xD;
             in safety run-in part of the study.&#xD;
&#xD;
         12. Any diseases or medical conditions, at the investigator's discretion, that may be&#xD;
             unstable or influence their safety or study compliance, including organ&#xD;
             transplantation, abuse of psychotropic medication, alcohol abuse or history of drug&#xD;
             abuse.&#xD;
&#xD;
         13. Other serious illness or medical conditions at the investigator's discretion, that may&#xD;
             influence study results, including but not limited to serious infection, diabetes,&#xD;
             cardiovascular and cerebrovascular diseases or lung disease.&#xD;
&#xD;
         14. Patients with a history of interstitial lung disease (ILD), drug-induced ILD,&#xD;
             radiation pneumonitis which required steroid treatment or any evidence of clinically&#xD;
             active ILD.&#xD;
&#xD;
         15. Pregnant or breast-feeding patients. Pregnancy refers to the state of a woman between&#xD;
             fertilization and the end of pregnancy confirmed by positive laboratory hCG test (&gt; 5&#xD;
             mIU/mL). Breast-feeding woman can become eligible for this study if she stops&#xD;
             breast-feeding, however, cannot restart the breast-feeding on/after the completion of&#xD;
             the study treatment.&#xD;
&#xD;
         16. Man and woman with childbearing potential (WOCBP refer to appendix 3) not using&#xD;
             effective contraception (refer to appendix 3) during the trial and within 6 months&#xD;
             after the end of treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Zhou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Haihe Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shun LU, Doctor</last_name>
    <phone>+86-21-22200000ext2153</phone>
    <email>shun_lu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaspreet Singh, Grewal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope &amp; Innovation</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen, Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Province Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejie Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chest Hospital of Anhui Province</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhong Min</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziping Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospita</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Fang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Medical College Hospital Affiliated to Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengzhi Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qitao Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan Cancer Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yijiang Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Harbin Medical University</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Yu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Province Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqiu Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanping Hu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaorong Dong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meiqi Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongqian Shu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuwei Cui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoling Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Shandong</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong University Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuwen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Bai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan university Shanghai cancer center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialei Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chest Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingzhi Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diansheng Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital，College of of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Province Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiping Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Province Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingya Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoyuki Nogami</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isamu Okamoto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terufumi Kato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Tanaka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidetoshi Hayashi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazumi Nishino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Sakakibara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haruki Kobayashi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koichi Goto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuichiro Ohe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiro Kodani</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.</citation>
    <PMID>11784875</PMID>
  </reference>
  <reference>
    <citation>Drilon AE CD, Ou S-H. Efficacy and safety of crizotinib in patients (pts) with dvanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol. 2016; 34:suppl; abstr 108.</citation>
  </reference>
  <reference>
    <citation>6. Felip E HL, Patel JD. Tepotinib in patients with advanced non-small cell lung cancer harboring MET exon 14-skipping mutations: Phase II trial. . J Clin Oncol. 2018; 36:suppl; abstr 9016.</citation>
  </reference>
  <reference>
    <citation>Yin L, Lu Y. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):553-559. doi: 10.3779/j.issn.1009-3419.2018.07.09. Review. Chinese.</citation>
    <PMID>30037377</PMID>
  </reference>
  <reference>
    <citation>Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018 Sep;123:76-82. doi: 10.1016/j.lungcan.2018.07.006. Epub 2018 Jul 6.</citation>
    <PMID>30089599</PMID>
  </reference>
  <reference>
    <citation>Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. J Thorac Oncol. 2016 Sep;11(9):1503-10. doi: 10.1016/j.jtho.2016.05.016. Epub 2016 May 30.</citation>
    <PMID>27257131</PMID>
  </reference>
  <reference>
    <citation>Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.</citation>
    <PMID>25971938</PMID>
  </reference>
  <results_reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </results_reference>
  <results_reference>
    <citation>Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.</citation>
    <PMID>20610543</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MET</keyword>
  <keyword>MET amplification</keyword>
  <keyword>MET over-expression</keyword>
  <keyword>C-Met Exon 14</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

